#xBio hashtag - Bluesky

4 weeks ago

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results Xenetic Biosciences (NASDAQ:XBIO) reported full-year 2025 results and scientific progress on its DNase I immuno-oncology program. Key points: net loss of $2.7 million, royalty revenue up ~19% to $3.0 million, and year-end cash of $7.9 million. The company advanced preclinical, translational and IND-enabling activities and supported investigator-initiated trials in PDAC and proposed LBCL/CAR-T combinations.

#XBIO Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences (NASDAQ:XBIO) announced its 2025 Annual Meeting of Stockholders was convened and adjourned on December 11, 2025 due to a lack of quorum.The meeting will reconvene virtually at 10:00 a.m. ET on Thursday, January 8, 2026. The record date for voting remains October 15, 2025. Stockholders who already voted do not need to re-submit votes; previously submitted proxies remain valid unless revoked.Stockholders who have not voted are urged to vote by 11:59 p.m. ET on January 7, 2026 via www.proxyvote.com or telephone 1-800-690-6903. Broker-held shares may have earlier deadlines. The reconvened meeting can be attended at http://www.virtualshareholdermeeting.com/XBIO2025.

#XBIO Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month

#XBIO Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences (NASDAQ:XBIO) reported third quarter 2025 results on November 13, 2025, highlighting continued preclinical progress on its systemic DNase I oncology program and partnerships to support investigator‑initiated studies.Key financials: Q3 net loss ~$0.5M; R&D +105.6% to ~$0.8M; Revenue +67.2% to ~$1.0M driven by Takeda sublicense royalties; quarter‑end cash ~$4.1M and subsequent October 2025 underwritten offering net proceeds of ~$3.9M to extend runway toward IND preparation and Phase 1 initiation.

#XBIO Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences (NASDAQ:XBIO) priced an underwritten offering of 735,000 shares of common stock at $6.12 per share for gross proceeds of approximately $4.5 million. The offering is expected to close on or about October 14, 2025, subject to customary closing conditions, with Canaccord Genuity as sole bookrunner.All shares are being offered by Xenetic and proceeds are intended for working capital and general corporate purposes. The offering is made under a Form S-3 shelf registration declared effective November 1, 2024 (File No. 333-282756); a final prospectus supplement will be filed with the SEC.

#XBIO Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

BREAKING NEWS: ( NASDAQ: #XBIO ) Xenetic Biosciences Inc. (NASDAQ: XBIO) Sets New 52-Week High in Wednesday Session

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

6 months ago

Nasdaq Gains 150 Points; US Mortgage Applications Decline - AlphaTON Capital (NASDAQ:ATON), Envoy Medical (NASDAQ:COCH)

Nasdaq Gains 150 Points; US Mortgage Applications Decline read more

#ATON #COCH #Earnings #Equities #GLTO #Mid #Morning #Market #Update #News #XBIO

Origin | Interest | Match

0 0 0 0

Stock Master

@stockmaster70.bsky.social

6 months ago

📢 Stocks Trending NOW: #BURU #POET #RKLB #TMC #ORCL #ASTS #XBIO #YYAI #UPC #JOBY

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Xenetic Advances Novel DNase-CAR T Cancer Therapy Program with Scripps, Reports $4.8M Cash Position Biotech firm strengthens Scripps collaboration on DNase-CAR T therapy for difficult cancers, advances toward Phase 1 trials. Q2 shows reduced expenses with $4.8M cash runway. Learn more.

#XBIO Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Revolutionary Cancer Treatment: Xenetic and Scripps Advance DNase-CAR-T Therapy for Lymphoma and Leukemia New research collaboration expands DNase-CAR-T therapy testing for lymphoma and leukemia. Breakthrough results show reduced tumor burden and extended survival. Learn more.

#XBIO Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend in Average Directional Index, Wed Jun 25th - #XBIO #VLCN #SIDU #VRA #UFPT #TWST #SPTN #RWAY #NKTA #LAB #IRON #HIT #GILT #CDZI #BCAL #AAOI #CARS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Xenetic Biosciences (NASDAQ:XBIO) reported its Q1 2025 financial results, highlighting progress in its DNase-based technology development. The company recorded a net loss of $0.9 million with revenue increasing 16.1% to $0.6 million compared to Q1 2024. Operating expenses decreased by 13.7% to $1.5 million. The company maintains $5.2 million in cash. Key developments include a partnership with PeriNess Ltd. for clinical studies on DNase platform treating relapsed/refractory osteosarcoma and Ewing sarcoma. Xenetic is advancing towards Phase 1 clinical trials for pancreatic carcinoma treatment, with completed preliminary studies on DNase I combinations with chemotherapy, immuno-therapies, and CAR-T therapy in colorectal cancer models.

#XBIO Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Breakthrough Cancer Research: DNase I Technology Enhances CAR-T Cell Effectiveness in Melanoma Latest preclinical data reveals how DNase I technology could improve CAR-T cell therapy effectiveness against solid tumors. Key findings from SITC presentation inside.

#XBIO Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Xenetic Biosciences Strengthens Cancer Research Pipeline While Maintaining $6.2M Cash Position Xenetic advances DNase-based cancer treatment development with key research partnerships, maintains $2.5M royalty stream and $6.2M cash position while reducing operational costs.

#XBIO Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success Groundbreaking preclinical data reveals DNase I enhances CAR T cell therapy effectiveness, showing reduced tumor burden and increased survival in melanoma studies. Phase 1 trials ahead.

#XBIO Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can Xenetic's DNase I Innovation Finally Crack the Solid Tumor Barrier for CAR-T Therapy? XBIO's research shows DNase I intervention targets neutrophil traps to improve CAR-T efficacy in melanoma, potentially overcoming solid tumor resistance.

#XBIO Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership Discover how Xenetic Biosciences is pushing boundaries in oncology research through an extended partnership with UVA, targeting breakthrough treatments for hard-to-treat cancers.

#XBIO Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 Xenetic advances DNase-based oncology platform showing enhanced efficacy in cancer treatment when combined with immunotherapy. Key research agreement extended with UVA.

#XBIO Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#XBIO Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

www.stocktitan.net/news/XBIO/xenetic-biosci...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #XBIO ) Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

#StockMarket #News

0 0 0 0